Aptahem AB (publ), announce today that the company’s largest shareholder, Ivar Nordqvist, suggests Dr Bert Junno to be elected new Chairman of the Board at the coming Extraordinary General Meeting on 25 September 2020. This after the former Chairman...
Read MoreAptahem AB (publ), announce today that the Chairman of the Board of Directors, Kjell G Stenberg, has requested his own resignation from the Board. Due to this, the Board of Directors will call for an Extraordinary General Meeting to...
Read MoreAptahem AB, a leading developer of aptamer-based drugs, announced today that the company is now starting large-scale manufacturing after LGC Bioresearch Technologies Inc. (LGC) completed the Process Development (PD) work enabling larger Pilot scale production campaigns of Apta -1....
Read MoreBioStock published an article on 10 July 2020 about Aptahem, which can be read in full below. Last night, Malmö-based Aptahem announced that they have entered a preclinical collaboration with the University Health Network in Toronto. The collaboration will...
Read MoreAptahem (publ) today announced the beginning of a collaboration with the University Health Network, a research hospital affiliated with University of Toronto in Canada. The collaboration aims to evaluate the anti-coagulant Apta-1 as an inhibitor of hyper inflammatory response...
Read MoreBioStock published an article on 1 July 2020 about Aptahem, which can be read in full below. At the end of last year, Aptahem entered a consortium with Örebro University with the aim of evaluating new strategies to reduce...
Read MoreAptahem (publ) is a biotech company developing aptamer-based pharmaceuticals for the treatment of life-threatening conditions, such as sepsis. A similar mechanism occurs in cardiovascular diseases where a combination of coagulation and inflammation are involved. Aptahem today announces that the...
Read MoreBioStock published an article on 24 June 2020 about Aptahem, which can be read in full below. For half a century Dexamethasone has been used to treat diseases such as rheumatoid arthritis and asthma. Four years ago, Malmö-based Aptahem...
Read MoreAptahem today informs that the company’s latest patent application has been registered in several countries and are subject to approval. The patent application, which is an international PCT application*, is a merger of two previous Europe applications and have...
Read MoreBioStock published an article on 29 April 2020 about Aptahem, which can be read in full below. Aptahem, whose primary drug candidate Apta-1 is being developed as an acute treatment for sepsis, recently announced that it is expanding its team...
Read More